Kornimate/medical-research-clean huggingface dataset:
automated arthritis detection using artificial intelligence on smartphone photographs

Conditions: Rheumatoid Arthritis &Amp; Other Inflammatory Polyarthropathies; Peripheral Spondyloarthritis; Inflammatory Arthritis

Summary: the investigators are testing the ability of convolutional neural networks (cnns), that is artificial intelligence, on smartphone photographs in detecting inflammatory arthritis. this promises to be an efficient, accurate, and non-invasive diagnostic tool that will significantly improve early detection and management of inflammatory arthritis.

over the past 4 years the investigators have aimed to help the early detection of arthritis leveraging artificial intelligence. this project aims to detect arthritis based on smart phone photographs of joint areas that make it scalable and available in the community. this group first developed a compelling proof-of-concept pipeline and models using 100 patients. (published in frontiers in medicine, nov 2023, wherein they demonstrated that this technology works with reasonable accuracy in the lab, viz technology readiness level currently stands at 3-4). they followed with a newer paper (submitted for publication, available on preprint server medrxiv) that trained two different cnns, a screening cnn on uncropped hands that distinguishes patients from controls followed by joint specific detections. the system involves supporting infrastructure that will enable efficient detection of arthritis. this includes 1. collection of photos in a standardized manner using custom designed boxes 2. using and testing a browser pipeline 3. the cnn models will be trained on the dataset of photographs taken in this and results will be deployed to doctors in the community. this ensures a doctor in the loop that can later take action on the results for further confirmatory tests or management. 4. understanding knowledge, attitude of patients and doctors towards ai in clinical decision making algorithms this is a prospective, non-interventional study and this project only involves an investigator taking a smartphone photograph of some joint areas kept in standardized positions. this involves no risk to the patient.

Eligibility criteria:
inclusion criteria: * inflammatory arthritis of any etiology exclusion criteria: * severe deformity that hampers standardization of photographs

Keywords: artificial intelligence for arthritis diagnosis
precise percutaneous coronary intervention plan (p3) study

Conditions: Stable Coronary Artery Disease

Summary: the precise percutaneous coronary intervention (pci) plan study is an investigator-initiated, international and multicenter study of patients with an indication for pci aiming at assessing the agreement and accuracy of the heartflow planner with invasive fractional flow reserve (ffr) as a reference.

multicenter study, including 120 patients at 5 centers in europe and asia. after identifying the presence of significant coronary stenosis by means of coronary angiography and invasive fractional flow reserve (ffr≤0.80) the patients will undergo the following procedures: invasive ffr with intravenous adenosine (i.e. pre- and post-pci). optical coherence tomography-guided pci (i.e. pre- and post-procedural imaging). pci with newer generation drug-eluting stent.

Eligibility criteria:
inclusion criteria: * coronary artery disease in a major epicardial vessel with an invasive fractional flow reserve (ffr) ≤0.80 * an indication to percutaneous coronary intervention exclusion criteria: - angiographic exclusion criteria 1. severely calcified lesion/vessel 2. bifurcation lesions. 3. ostial lesions. 4. left main disease. 5. severe vessel tortuosity. clinical exclusion criteria 1. chronic obstructive pulmonary disease 2. contraindication to adenosine 3. nyha class iii or iv, or last known left ventricular ejection fraction \<30% 4. uncontrolled or recurrent ventricular tachycardia 5. atrial fibrillation, flutter or arrhythmia 6. history of recent stroke (≤90 days) 7. history of acute coronary syndrome (≤90 days) 8. prior myocardial infarction 9. history of ischemic stroke (\>90 days) with modified rankin score ≥ 2 10. history of any hemorrhagic stroke 11. previous revascularization (pci or coronary artery bypass grafting) 12. active liver disease or hepatic dysfunction, defined as ast or alt \> 3 times the uln 13. severe renal dysfunction, defined as an egfr \<30 ml/min/1.73 m2 14. body mass index\>35 kg/m2 15. nitrate intolerance 16. contra-indication to heart rate lowering drugs imaging-related 17. insufficient coronary ct angiography image quality.
the cirrhosis outpatient optimization, readmission & safety study

Conditions: Cirrhosis

Summary: a prospective series comparing care incorporating home monitoring and liver care coordination to conventional care for patients with cirrhosis.

telemonitoring has been suggested to have potential benefits in patients with cirrhosis. however, to date, no prospective studies exist to support this idea. hence, the investigators study would like to explore the use of home telemonitoring devices with vital sign capturing capabilities in recently-discharged patients with cirrhosis to decrease 30-day readmissions, mortality and costs. this is prospective, randomized controlled trial comparing two strategies of post-discharged care in patients with cirrhosis-related hospitalizations. first treatment arm will incorporate the vivify home monitoring device into post hospital care.home monitoring kits include a tablet with wireless internet and vital sign monitoring capabilities (temperature, blood pressure, heart rate, weight and pulse oximetry if needed) and the device has the ability to trigger an alert to the "liver care coordinator." second treatment arm will continue the standard of care therapy that all post- hospitalized patients receive upon discharge, i.e. return to clinic appointments, education regarding any signs or worsening symptoms to watch for, as well as contact numbers to connect with their doctor or nurse.

Eligibility criteria:
inclusion criteria: 1. ascites requiring paracentesis during the hospitalization 2. hepatic encephalopathy defined as altered mental status that improves after treatment with lactulose 3. variceal hemorrhage, defined as clinically significant gastrointestinal bleed (tachycardia, hypotension, requirement for blood transfusion, or \>2g drop in hemoglobin) and varices seen on endoscopy 4. spontaneous bacterial peritonitis defined as \>250 polymorphonuclear cells per high-power field and/or monomicrobial culture in the ascetic fluid 5. renal failure in the presence of ascites, defined as a rise in the serum creatinine by 0.5mg/dl (to \>1.5mg/dl), with ascites documented on physical exam or ultrasound, or admitted on diuretics for the treatment of ascites 6. hyponatremia, defined by serum sodium \<130 on admission labs 7. hepatocellular carcinoma as seen on arterial phase mri or liver biopsy, if tumor is treated and fits within milan criteria exclusion criteria: * admissions for scheduled or elective procedures * patients with a comorbid conditions with a life expectancy of less than 12 months or ones that may confound a patient's clinical course * hepatocellular carcinoma * hepatorenal syndrome * hepatopulmonary syndrome * metastatic cancer * chronic kidney disease (pre-dialysis, dialysis) * congestive heart failure * diagnosed dementia * hiv/aids * pregnancy or planned pregnancy during the study * those managed by palliative care * patients with liver transplants prior to or during the index hospitalization * patients unable to understand study procedures/instructions/use of the home monitoring device * patients unable to stand for \<1 minute * patients living in nursing homes or similar institutions
tocosol(tm) paclitaxel in metastatic or locally advanced unresectable transitional cell carcinoma of the urothelium

Conditions: Bladder Neoplasms; Ureteral Neoplasms; Urethral Neoplasms; Carcinoma, Transitional Cell

Summary: phase 2b, multicenter study evaluating the safety and efficacy of weekly tocosol paclitaxel in taxane-naive patients receiving second line chemotherapy for metastatic or locally advanced, unresectable transitional cell carcinoma of the urothelium


Eligibility criteria:
inclusion criteria: * histologic diagnosis of transitional cell carcinoma (tcc) of the urothelium including bladder, renal pelvis, ureter, or urethra * stage iv disease * one and only one prior systemic cytotoxic chemotherapy regimen administered as adjuvant or neoadjuvant chemotherapy or to treat locally advanced or metastatic disease * adequate hematologic function (anc \>/= 1500 cells/mm3 \& platelet count \>/= 100,000/mm3) * serum creatinine \</= 2.0 mg/dl * total bilirubin \</= 1.5 mg/dl * sgot \& sgpt \</= 3 times upper limit of institutional normal values * pt (inr) \& ptt within institutional lab normal range * karnofsky performance status of 60-100% * at least one unidimensionally measurable lesion, suitable for radiographic evaluation of disease response, consistent with recist criteria * signed irb/ec approved informed consent * life expectancy of at least 12 weeks * 18 years of age or older * fully recovered from any previous surgery * not pregnant and willing to use a medically effective form of contraception during periods of chemotherapy treatment (both males and and females) * agree not to take vitamin e supplementation while receiving study medication * willing to participate in requested follow-up evaluations * willing to permit treating physicians to provide information to sonus regarding disease status and survival for 2 years after first dose of study drug exclusion criteria: * prior taxane-containing chemotherapy including taxol(r) (paclitaxel) or generic equivalent, or taxotere(r) (docetaxel) * peripheral neuropathy nci-ctc grade 2 or greater * wide-field radiation, cytotoxic chemotherapy or hormonal therapy within 4 weeks of first dose, or mitomycin or nitrosoureas within 6 weeks of first dose, of study drug * an investigational agent within 4 weeks of first dose of study drug * concurrent anticonvulsants known to induce p450 isoenzymes * patients who are pregnant or lactating * a history of carcinoma of another primary site (other than non-melanoma skin cancers or carcinoma-in-situ of the cervix) within the previous 5 years, unless metastatic disease has been biopsied and documented to be tcc * bone metastasis, effusions, ascites or elevated tumor markers as the only evidence of metastatic tcc * brain metastasis * active bowel obstruction * active, serious infection or other serious medical problems (other than tcc) likely to impair completion of the study protocol
tms in preclinical and prodromal ad: modulation of brain networks and memory

Conditions: Alzheimer Disease; Mild Cognitive Impairment; Aging

Summary: the purpose of this study is to assess the effects of non-invasive brain stimulation on memory in cognitively unimpaired older adults and in patients amnestic mild cognitive impairment (amci) due to alzheimer's disease (ad). this study will use repetitive transcranial magnetic stimulation (rtms) to stimulate nodes of the default mode network (dmn)- which is thought to support episodic memory and to be affected by alzheimer's pathology. we will use functional connectivity mri (fcmri) to assess changes in functional network architecture following the stimulation. we will also assess putative cognitive improvements resulting from the stimulation by in-depth memory testing.


Eligibility criteria:
inclusion criteria: 1. between the ages of 60-85 2. all participants will be native english speakers 3. willing and able to consent to the protocol and undergo imaging and neuropsychological testing at the specified time points 4. participants with amci will be asked to bring a study partner to all visits 5. only patients with very mild or mild cognitive impairment (cdr 0.5 or cdr 1) will be included in the prodromal ad cohort exclusion criteria: 1. history of head trauma involving loss of consciousness or alteration in consciousness 2. another major neurologic or psychiatric condition 3. known presence of a structural brain lesion (e.g. tumor, cortical infarct) 4. any contraindication to mri, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body 5. longstanding premorbid history (i.e. longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed 6. any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol. 7. unwilling to return for follow-up, undergo neuropsychological testing, tms, and mr imaging
real-world study on secukinumab effectiveness in biologic-naïve ankylosing spondylitis (as) patients in korea.

Conditions: Ankylosing Spondylitis

Summary: this is an observational study to evaluate the effectiveness and safety of secukinumab in participants with as who have never used tnfi, jaki, or il-17i drugs before.

this study is an observational study to evaluate the effectiveness and safety of secukinumab in patients with ankylosing spondylitis who are naive to tnfi/jaki/il-17i in korea. subjects will be recruited from 10 institutions in korea. the enrollment period is 8 months from the initiation at the first institution and the follow-up periods are 28 weeks(±4 weeks). data will be gathered at initial visit, 16 weeks(±4 weeks), and 28 weeks(±4 weeks). secukinumab is prescribed within the scope of labeling approved in korea.

Eligibility criteria:
inclusion criteria: 1. subjects diagnosed with ankylosing spondylitis (as), as defined by the modified 1984 new york criteria 2. subjects who have symptoms of active disease at screening and baseline, as evidenced by basdai score of ≥ 4 3. subjects who have never used tnfi, jaki, or il-17i drugs before 4. patients suitable for secukinumab treatment within the scope of labeling by the ministry of food and drug safety 5. subjects who have a time of less than 5 years since as diagnosis 6. subjects who are above the age of 18 years and below 40years old 7. subjects who give informed consent form to participate in the study exclusion criteria: 1. subjects who are in a medical or psychological condition which may prevent them from participating in the study for the study period(28±4 weeks) 2. subjects who have congenital/traumatic spinal deformities 3. subjects currently enrolled in other clinical studies 4. subjects who have any contraindications to secukinumab treatment

Keywords: secukinumab ankylosing spondylitis biologic naive real world study korea rheumatology as research rheumatic disease biologics clinical effectiveness
detection of electrocardiographic brugada patterns using high precordial leads

Conditions: Brugada ECG Patterns

Summary: detection of prevalence of brugada patterns in our locality in asymptomatic patients , by standard 12 lead ecg level and high precordial ecg level, measuring how much the high precordial leads is more sensitive in brugada patterns detection than standard level 12 lead ecg in our upper egyptian population.

detection of prevalence of brugada patterns in our locality in asymptomatic patients , by standard 12 lead ecg level and high precordial ecg level, measuring how much the high precordial leads is more sensitive in brugada patterns detection than standard level 12 lead ecg in our upper egyptian population. the study will include patients fulfilling our criteria presenting to cardiology outpatient clinic and emergency room of assiut university hospitals.

Eligibility criteria:
inclusion criteria: 1. patients with ihd,htn,dm with no organic heart disease by echo. 2. healthy persons with normal structure heart by echo. exclusion criteria: 1. acute coronary syndrome. 2. cardiomyopathy. 3. severe valvular heart disease. 4. htn heart disease with lvh. 5. malignancy.
open label extension of lipolat-cs202

Conditions: Glaucoma

Summary: this is an open-label, observational extension of patients who received polat-001 in lipolat-cs202.


Eligibility criteria:
* inclusion criteria 1. successful completion of 3 months of participation in study lipolat-cs202. 2. treatment with polat-001 in study lipolat-cs202. 3. able and willing to give signed informed consent and follow study instructions. * exclusion criteria excluded from the study will be individuals with the following characteristics: 1. the development, during study lipolat-cs202, of any exclusion criteria from that study (e.g., concomitant medication or co-morbid disease).
comparative analysis of the microcirculation during cardiac surgery with minimal invasive versus conventional extracorporeal circulation

Conditions: Coronary Artery Disease; Aortic Valve Stenosis; Mitral Disease

Summary: the aim of the proposed study is to evaluate microcirculatory alterations in patients undergoing open heart surgery with minimal invasive versus conventional extracorporeal circulation. positive clinical results evidenced with goal-directed perfusion and cerebral oximetry monitoring could be attributed to preserved microcirculation at tissue level.

the aim of the proposed study is to evaluate microcirculatory alterations in patients undergoing open heart surgery with minimal invasive versus conventional extracorporeal circulation. microcirculatory changes during cardiac surgery have been investigated mainly during coronary procedures using the conventional extracorporeal circulation.there is no single study in the literature investigating microcirculatory alterations using a perioperative strategy of "physiologic" perfusion. positive clinical results evidenced with goal-directed perfusion and cerebral oximetry monitoring could be attributed to preserved microcirculation at tissue level. all patients will follow the same anaesthetic and perfusion protocol. the patients will be randomized to two arms: 1. patients operated with minimal invasive extracorporeal circulation (miecc) 2. patients operated with conventional cardiopulmonary bypass (ccpb) the protocol for the evaluation of microcirculation will be based on: * cerebral near-infrared spectroscopy (rsco2) measurements (invos, covidien-medtronic inc.). * nirs-based cerebral autoregulation monitoring: analog arterial blood pressure signals will be digitized and then processed with the digital nirs signals using a personal computer and a special icm software (university of cambridge, cambridge, uk). monitoring cerebral autoregulation ensures adequate renal perfusion. hence, brain can be used not just as a target but also as an index organ indicating adequacy of perfusion. * somatic near-infrared spectroscopy (rsso2) measurements (invos, covidien-medtronic inc.). * sublingual mucosal microcirculation measurements during surgery using side dark field (sdf) imaging (microscan, microvision medical, amsterdam, the netherlands). all measurements will be performed at the following time points: t0: after induction of anaesthesia t1: after initiation of cardiopulmonary bypass t2: 10 minutes after cross- clamping the aorta t3: 10 minutes before removing the aortic cross-clamp t4: after weaning from extracorporeal circulation

Eligibility criteria:
inclusion criteria: * patients undergoing undergoing open heart surgery with accepted indications under extracorporeal circulation exclusion criteria: * patients undergoing emergency surgery * patients in preoperative cardiogenic shock with evidence of tissue malperfusion * patients with severe peripheral vascular disease * patients unable to give informed consent

Keywords: extracorporeal circulation minimal invasive extracorporeal circulation cardiopulmonary bypass cerebral oximetry microcirculation near-infrared spectroscopy
tele-yoga therapy for chronic pain

Conditions: Chronic Pain

Summary: chronic pain is highly prevalent and associated with a large symptom burden, that is had been more concerning during covid-19 outbreak and lockdown. benefits of yoga in chronic pain management are very well known. with this background we developed tele-yoga therapy program and evaluated the success of this single arm study.


Eligibility criteria:
inclusion criteria: * chronic pain for at least 3 months * having access to internet and video calls exclusion criteria: * pregnant or breast-feeding women, * patients not willing to give written consent * patients with severe psychiatric or personality disorder * malignancy

Keywords: tele-yoga therapy chronic pain
efficacy study of kinesio taping to treat muscular and joint problems in chronic venous insufficiency

Conditions: Chronic Venous Insufficiency

Summary: the purpose of this study is to analyze the effects of kinesio taping on gastrocnemius muscle activation during gait and on range of ankle motion in postmenopausal females with chronic venous insufficiency in initial stages in comparison to a placebo control group.

chronic venous insufficiency (cvi) is a very common disease. patients with this pathology present peripheral muscle pump impairment and restricted range of ankle motion. few data are available on the use in chronic venous insufficiency patients of kinesio taping, a physical therapist's elastic dressing that permits action on muscle activity and joint range.

Eligibility criteria:
inclusion criteria: * age between 50 and 75 years. * mild-moderate chronic venous insufficiency (grades c1, c2, and c3 on clinical-etiologic-anatomic-pathophysiologic (ceap) scale) exclusion criteria: * chronic venous insufficiency (\> grade c3) * arterial disorders * cardiorespiratory disease * contraindications for kinesio taping technique including thrombosis, wounds, severe trauma, generalized edema secondary to cardiac or renal problems, carcinomas, intolerability of/allergy to surgical tape and pregnancy.

Keywords: chronic venous insufficiency kinesio taping electromyography range of ankle motion
comparative effectiveness of three lucid dreaming and sleep hygiene techniques

Conditions: Anxiety

Summary: in this study, the investigators will compare traditional lucid dream induction techniques, stress reduction strategies, and sleep hygiene across three study groups: (1) lucid dream and stress reduction techniques, and sleep hygiene; (2) lucid dream reduction and sleep hygiene; and (3) sleep hygiene. participants will be first-year occupational therapy students embarking upon their first full-time 3-month clinical internship. enrolled participants will be randomized to one of the three groups. the intervention will span 12 weeks and allow for participants to learn about and practice lucid dream induction, stress management, and sleep hygiene in bi-monthly online group sessions and through daily home exercises.

a significant impediment to completing academic health care programs is student stress level, which have been reported to be increasing in the last decade. many students are not prepared for the rigor and intensity of their first clinical internship and experience exacerbations of stress and anxiety at this time. there is evidence that lucid dream induction methods have effectively alleviated stress and anxiety in veterans with post-traumatic stress disorder, and depression in community dwelling adults. although lucid dream techniques have been used to manage anxiety in some populations, it has never been used to help health care students on clinical internship experiencing heightened stress levels. in this study, the investigators aim to determine whether lucid dream induction techniques combined with stress management and sleep hygiene could effectively help students on their first clinical internship to better manage stress and anxiety. the investigators hope to gain a greater understanding of which of three study conditions can best alleviate stress and anxiety in participants.

Eligibility criteria:
inclusion criteria: * current occupational therapy student attending columbia university and participating in clinical internship exclusion criteria: * none

Keywords: dreaming sleep dream